Dendreon — Merger or Acquisition (July 2003)
39 slides from Dendreon's merger presentation, Jul 7, 2003
Slide 1: Building a Premier Biotechnology Company
Dendreon Corporation Corvas International Building a Premier Biotechnology Company
Slide 2: Forward-Looking Statement Disclaimer
Forward-Looking Statement Disclaimer This presentation includes forward-looking statements, including statements about Dendreon’s proposed acquisition of Corvas, post-closing business synergies and product opportunities, and product development and commercialization. Actual results may differ materi
Slide 3: Additional Information About the Acquisition and Where to Find It
Additional Information About the Acquisition and Where to Find It Dendreon and Corvas have filed with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4, which contains a joint proxy statement/prospectus with respect to the combination and other relevant materials. I
Slide 4: Dendreon Corporation
Dendreon Corporation Developing targeted therapies for the treatment of cancer • Immunotherapeutic cancer programs -Provenge®, MylovengeTM, APC8024, Trp-p8, NY-ESO, CEA, MN, Telomerase • Monoclonal antibodies and small molecules -Trp-p8, DN1921, DN1924 • Industry leading collaborators -Genentech, In
Slide 5: Momentum Continues in 2003
. Momentum Continues in 2003 Corvas Acquisition • Stock for stock transaction • Valued to $73 M, based on Dendreon closing stock price of $5.79 on 2/24/03, an 83% premium to Corvas’ stock price as of the same date • Dendreon stockholders will own 71.6% and Corvas stockholders will own 28.4%, based o
Slide 6: Combining Strengths
Combining Strengths Technology • Broad oncology portfolio covering 4 platforms • 5 ongoing clinical programs • Enhanced intellectual property estate, 87 issued U.S. patents • Small molecule, medicinal chemistry expertise Operations • Experienced management team • Clinical development expertise • Res
Slide 7: Breadth in Oncology
Breadth in Oncology Vaccine Targets Antibodies Small Molecules Prodrug Program NY-ESO Trp-p8 Trp-p8 uPA CEA DN1924 Urokinase (uPA) Inhibitors Other Serine Proteases MN DN1921 (autoimmune diseases) Matriptase Inhibitors Telomerase Serine Protease Inhibitors Trp-p8 ARF DNDN CVAS
Slide 8: Advanced Clinical Trial Pipeline
Advanced Clinical Trial Pipeline Product/Target Phase 1 Phase 2 Phase 3 Provenge ® Androgen Independent Prostate Cancer Completed D9901 D9902 Androgen Dependent Prostate Cancer P-11 (Provenge alone) P-16 (Provenge+Avastin) Mylovenge ™ Multiple Myeloma rNAPc2 Acute Coronary Syndromes APC8024 Breast,
Slide 9: Leading Cancer Vaccine Platform
Leading Cancer Vaccine Platform • Well validated and well characterized antigen targets manufactured as recombinant proteins • Proprietary Antigen Delivery Cassette TM technology • Induces strong and reproducible immune responses
Slide 10: Provenge Phase 3 Trial (D9901)
Provenge ® Phase 3 Trial (D9901) Double Blind, Placebo Controlled Vaccinate at Weeks 0 2 4 • First randomized, double blind, placebo controlled Phase 3 study of a cancer vaccine • Primary endpoint – Median time to objective disease progression • Advanced androgen independent prostate cancer patients
Slide 11: Primary Efficacy Analysis (ITT)
Primary Efficacy Analysis (ITT) Time from randomization to disease progression Provenge (n=82) Placebo (n=45) p=0.085 HR=1.394 (95% CI 0.953 - 2.037) Proportion Without Progression Time to Disease Progression (weeks) Phase 3 Trial #D9901
Slide 12: Gleason Score
Gleason Score • Routinely performed prostate grading system - Histologic measure of aggressiveness of tumor - Patients with score of £ 7 tend to have better prognosis • Majority (75%) of androgen independent patients have a score of 7 or less • Pre-specified subgroup for analysis • Single most impor
Slide 13: Efficacy Analysis: Gleason
Efficacy Analysis: Gleason £ 7 Time to objective disease progression (Kaplan-Meier method): Primary Efficacy Analysis, Gleason Score £ 7, Intent-to-Treat Patients Provenge (n=50) Placebo (n=25) P=0.002 HR=2.222 (95% Cl: 1.331 – 3.710) Proportion Progression Free Time (weeks) Phase 3 Trial #D9901
Slide 14: Comparison of Gleason Subgroups
Comparison of Gleason Subgroups Subgroup Analysis: Gleason £ 7 Subgroup Analysis: Gleason ³ 8 Provenge (n=50) Placebo (n=25) Provenge (n=32) Placebo (n=20) log rank p=0.002 log rank p=0.043 Proportion Progression Free Time (weeks) Proportion Progression Free Time (weeks) Phase 3 Trial #D9901
Slide 15: Progression Analysis: Gleason
Progression Analysis: Gleason £ 7 Time to Progression (weeks) Provenge (N=50) Placebo (N=25) Treatment Effect Median 16.0 9.0 1.78 Progression Free Survival Rate (percent) Months Provenge Placebo Treatment Effect 34.7 4.0 8.7 17.7 4.0 4.4 10.1 >10.1 6.7 > 6.7 Phase 3 Trial #D9901
Slide 16: Secondary Endpoint
Secondary Endpoint Time to Onset of Disease-Related Pain (Gleason £ 7 and ³ 8) Gleason £ 7 Gleason ³ 8 [CHART] [CHART] Phase 3 Trial #D9901
Slide 17: Provenge Very Well Tolerated
Provenge Very Well Tolerated* APC8015 (n=82) Placebo (n=45) Median Duration (days) Event [n(%)] Rigor 49 (59.8) 3 (6.7) 1.0 Pyrexia 24 (29.3) 1 (2.2) 2.0 Headache NOS 11 (13.4) 1 (2.2) 1.0 Paresthesia 11 (13.4) 1 (2.2) 2.0 Dyspnea 9 (11.0) 1 (2.2) 1.0 Number (%) of patients with Adverse Events *Occu
Slide 18: Provenge Trial D9902B
Provenge Trial D9902B • Special Protocol Assessment received from FDA – D9902B will serve as basis for BLA application • Trial enrolling AIPC patients with Gleason score £ 7 • Approximately 275 patients will be enrolled into study to support BLA
Slide 19: Provenge Collaboration Discussions
Provenge Collaboration Discussions • Discussions progressing as planned • Large market, data and regulatory plan have driven interest • Competitive process • Will be structured as co-development and co-promotion agreement • Global agreement minus Asia and Oceania
Slide 20: APC8024 Phase Trials
APC8024 Phase 1 Trials Patient Population • 18 patients enrolled; 16 evaluated • Advanced, metastatic breast cancer patients • Her-2 positive (2+, 3+) • Failed multiple courses of chemotherapy including 15/16 who failed Herceptin • Historical median time to progression 3-6 months Endpoints • Safety
Slide 21: APC8024 Clinical Response
APC8024 Clinical Response Clinical Benefit 25% (4/16 patients evaluated) Partial Response*: 1 patient, lasting more than 25 weeks Ongoing Stable Disease: 1 patient stable 48+ weeks 2 patients stable for more than one year No significant side effects reported, no evidence of any cardio toxicity * As
Slide 22: Dendreon & Genentech: Trp-p8 Collaboration
Dendreon & Genentech Trp-p8 Collaboration
Slide 23: Trp-p8 Characteristics
Trp-p8 Characteristics • Trans-membrane voltage gated Ca2 + channel • Over-expressed in breast, prostate, lung and colon cancers as well as hyperplastic prostate • Multiple therapeutic opportunities - Vaccines - Monoclonal antibodies - Small molecules References: U.S. Patent 6,194,152: Prostate tumo
Slide 24: In Normal Human Tissue, Trp-p8 Expression is Restricted to the Prostate
In Normal Human Tissue, Trp-p8 Expression is Restricted to the Prostate [CHART]
Slide 25: Trp-p8 is Detected in Primary Cancer Samples by In Situ Hybridization
Trp-p8 is Detected in Primary Cancer Samples by In Situ Hybridization Tissue Type Prostate Adeno Ca Breast Adeno Ca Melanoma Colorectal Adeno Ca Lung Ca Number of samples positive/studied Normal Breast Tissue Breast/CA RNA Tissue [GRAPHIC] Normal Colon Tissue Colon/CA RNA Tissue [GRAPHIC]
Slide 26: Trp-p8 – Architecture
Trp-p8 – Architecture
Slide 27: Genentech Trp-p8 Collaboration
Genentech Trp-p8 Collaboration • Structured as a co-development, co-promotion agreement with profit sharing rights in the U.S. • Significant upfront and milestone payments • Genentech responsible for manufacturing and funds majority of manufacturing and clinical trial costs • Leverage Corvas’ medici
Slide 28: Collaboration Milestones
Collaboration Milestones • Equity purchases and cash milestone payments • Milestone Events - At deal signing - Drug candidate identification - IND filing - Clinical trial milestones - BLA submission - BLA approvals • Total milestone payments could exceed $110 Million
Slide 29: Corvas Oncology Programs
Corvas Oncology Programs Dendreon Corporation Corvas International
Slide 30: Serine Protease Cancer Programs
Serine Protease Cancer Programs • Relevant for prostate cancer • Most well known is PSA • Provide a number of therapeutic opportunities - Inhibition with small molecules or monoclonal antibodies - As a target for monoclonal antibodies and therapeutic vaccines - Leverage enzymatic activity for delive
Slide 31: Protease Activated Cancer Therapy (PACT) Program
Protease Activated Cancer Therapy (PACT) Program [GRAPHIC]
Slide 32: CVS-10290 PK—Acute dose
CVS-10290 PK—Acute dose of 25mg/kg CVS-10290, IP in DU145 bearing nude mice • Dox peaks at 4 hours in tumors • At 24 hours dox is still detectable in tumors JB017 25mg/kg CVS-10290 PK in nude mice/DU145 tumors JB017 25mg/kg CVS-10290 PK in nude mice/DU145 tumors [CHART] [CHART]
Slide 33: CVS-10290 Efficacy Study Q1dx5
CVS-10290 Efficacy Study Q1dx5 DU145 Tumor Volume Rx Q1 Dx5 d0-4 (imp -29) [CHART] Dose Group max group % body weight loss % Tumor growth inhibition t test (p-value) Control - Dox 1.0mg/kg -12% 0.1980 3/10 toxic deaths CVS-10290 20mg/kg -9% 0.0112
Slide 34: Corvas Cardiovascular Program
Corvas Cardiovascular Program Dendreon Corporation Corvas International
Slide 35: rNAPc2 Potent Anticoagulant
rNAPc2 Potent Anticoagulant • Acts at initiation of coagulation cascade by blocking Tissue Factor/Factor VIIa complex • Produces sustained suppression of thrombin generation – a key element in acute coronary syndrome (ACS) • Potent and prolonged duration of action • May complement downstream product
Slide 36: Pro Forma Balance Sheet
Pro Forma Balance Sheet Quarter Ending March 31, 2003 ($ in millions) Pro Forma Cash, cash equivalents, short-term & long-term investments $133.8 Working capital 88.7 Total assets 143.6 Total stockholders’ equity 107.6
Slide 37: Expected Milestones and News Flow
Expected Milestones and News Flow Type 2003 2004 2005 Clinical Data Presentations at upcoming scientific meetings. Regulatory Fast track designation — Provenge Preclinical Milestone Trp-p8 Mab lead selection and DNA milestone payment Clinical Trials Complete Phase II Mylovenge studies Clinical Trial
Slide 38: The New Dendreon
The New Dendreon • Creating a top tier biotech company • Validated therapeutic cancer platform - Near-term market opportunities - Significant clinical benefit demonstrated with Provenge ® • Broad portfolio includes vaccines, monoclonal antibodies, small molecules and prodrugs • Industry leading part
Slide 39: Dendreon Corporation
Dendreon Corporation © Dendreon 2003